The role of protein tyrosine kinases in CYP1A1 induction by omeprazole and thiabendazole in rat hepatocytes.
Benzimidazoles compounds like omeprazole (OME) and thiabendazole (TBZ) mediate CYP1A1 induction differently from classical aryl hydrocarbon receptor (AhR) ligands, 3-methylcholanthrene (3-MC) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). To clarify the involvement of an intracellular signal pathway in CYP1A1 induction by OME and TBZ, the TBZ, OME and 3-MC signal-transducing pathways were compared by using specific protein tyrosine kinase inhibitors in primary culture of rat hepatocytes. The effect of OME and TBZ (75-250 microM) on cytochrome P450 1A1 (CYP1A1) expression was therefore studied in primary cultures of rat hepatocytes after 24 h, 48 h and 72 h of exposure. Both compounds provoked a dose- and time-dependent increase in CYP1A1 (EROD activity, protein and mRNA levels), but OME was less effective at all the concentrations and times tested. The mechanism of benzimidazole-mediated induction of CYP1A1 was investigated by comparison with 3-MC, a prototypical AhR ligand. As expected, OME and TBZ were unable to displace [(3)H]-TCDD from its binding sites to the AhR in competitive binding studies. Moreover, classic tyrosine kinase inhibitor herbimycin A (HA) inhibited the two benzimidazoles-mediated CYP1A1 inductions, but only partially inhibited the 3-MC-mediated one. Another two tyrosine kinase inhibitors, Lavendustin A (LA) and genistein (GEN), had no effect on CYP1A1 induction by benzimidazoles and 3-MC. These results are consistent with the implication of a tyrosine kinase, most probably the Src tyrosine kinase, in the mechanism of CYP1A1 induction in rat hepatocytes.
Laboratoire de Pharmaco-toxicologie cellulaire et moléculaire, INRA, B.P. 2078, 06606, Antibes, France. lemaireg@yahoo.com
G
G
Lemaire
C
C
Delescluse
M
M
Pralavorio
N
N
Ledirac
P
P
Lesca
R
R
Rahmani
D000818:Animals; D001551:Benz(a)Anthracenes / Q000494:pharmacology; D016227:Benzoquinones; D002478:Cells, Cultured; D019363:Cytochrome P-450 CYP1A1 / Q000096:biosynthesis* / Q000235:genetics; D004790:Enzyme Induction; D004791:Enzyme Inhibitors / Q000494:pharmacology; D022781:Hepatocytes / Q000187:drug effects / Q000201:enzymology*; D047029:Lactams, Macrocyclic; D008297:Male; D008748:Methylcholanthrene; D009853:Omeprazole / Q000494:pharmacology* / Q000633:toxicity; D000072317:Polychlorinated Dibenzodioxins / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*; D011809:Quinones / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D018336:Receptors, Aryl Hydrocarbon / Q000378:metabolism; D017828:Rifabutin / Q000031:analogs & derivatives; D013827:Thiabendazole / Q000494:pharmacology* / Q000633:toxicity
D001551:Benz(a)Anthracenes; D016227:Benzoquinones; D004791:Enzyme Inhibitors; D047029:Lactams, Macrocyclic; D000072317:Polychlorinated Dibenzodioxins; D011809:Quinones; D012333:RNA, Messenger; D018336:Receptors, Aryl Hydrocarbon; D017828:Rifabutin; D008748:Methylcholanthrene; C020754:herbimycin; D019363:Cytochrome P-450 CYP1A1; D011505:Protein-Tyrosine Kinases; D009853:Omeprazole; D013827:Thiabendazole